You are here: Home » PTI Stories » National » News
Business Standard

Bengal Chemicals can supply only 10 lakh hydroxy-chloroquine

Health Medical Pharma

Press Trust of India  |  Kolkata 

PSU pharma company Bengal Chemicals and Pharmaceuticals Ltd (BPCL) on Tuesday said it can provide only a maximum of 10 lakh hydroxy-chloroquine tablets due to the shortage of a key component, Active Pharmaceutical Ingredient (API).

The Indian Council of Medical Research (ICMR) has recommended the use of hydroxy-chloroquine for healthcare workers involved in the care of suspected or confirmed Covid- 19 cases and the asymptomatic household contacts of lab- confirmed cases as a preventive treatment measure.

Bengal Chemicals is possibly the only company from this part of the country having the capacity to produce hydroxy-chloroquine.

"Whatever raw material (API) we have that can be good for only 10 lakh malaria tablets (having hydroxy- chloroquine)," BPCL managing director PM Chandraiah told PTI.

API is the term used to refer to the biologically active component of a drug product such as tablet, capsule.

India imports 80 per cent of API from China, from where the novel coronavirus originated, to meet its requirements.

"In India, only the private sector IPCA produces API and we had been told that we are in the queue and our turn will come in May-June," he said.

According to the data updated Tuesday morning, the total number of COVID-19 cases rose to 492, including 446 active cases.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, March 24 2020. 16:54 IST